JeannetteKatzir/iStock via Getty Images
- A Dutch independent ethics committee has given Cybin (NYSE:CYBN) permission to begin dosing in a first-in-humans trial of CYB004, its deuterated DMT molecule for generalized anxiety disorder.
- The company said this version on DMT overcomes limitations of the regular version through improved bioavailability and longer duration of action compared to when given intravenously and inhaled.
- Cybin has a composition of matter patent for CYB004 in force until 2041.
- Check out this recent episode of The Cannabis Investing Podcast that discusses how to evaluate psychedelic stocks.